Invivyd Completes Enrollment Phase 3 LIBERTY Trial Of Covid-19 Monoclonal Antibody VYD2311 With An mRNA Covid-19 Vaccine, Topline Data Expected in Q3 2026
Benzinga · 06/16 11:14
Share
Listen to the news
- Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparison between COVID antibody prophylaxis and COVID vaccine.
- LIBERTY is part of Invivyd's broader REVOLUTION clinical program, including DECLARATION, designed to generate medical practice-changing data to support VYD2311, a potential new option for prevention of COVID-19
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved